Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars in its portfolio including nine biosimilars in development.

1. Research Report on Sandoz: Biosimilars
Company Analysis
This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and
threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key
product profiles, examining key drivers and resistors to development, market sizing, specifics of
development such as clinical trials (where available) for each key biosimilar molecule in
development.
Features and benefits
 Strategic insight into the key strategies that have shaped the company's progress and/or will define
its outlook going forward.
 Provides an indication of how biosimilars fit into the wider company context, and a history of deals
& alliances.
Highlights
Sandoz is the only company with three marketed biosimilars in Europe, each of which is now the
leading biosimilar in its respective market segment. The firm also has a wide variety of biosimilars
in its portfolio including nine biosimilars in development.
Your key questions answered
 See how Sandoz became the first generics company to gain approval for a biosimilar product
 Evaluate the firm's wide variety of biosimilars in its portfolio, including nine biosimilars in
development
Buy Your Copy of Report: http://www.reportsnreports.com/reports/175349-sandoz-biosimilars-
company-analysis.html
Published: July 2012
No. of Pages: 37
Price Single User License: US $ 3800 Price Corporate User License: US $ 9500

2. Table Of Contents
ABOUT THIS REPORT
CHAPTER STRUCTURE
Executive summary
Strategic insight
Product analysis
Operating performance
Company introduction
DATA SOURCING
Sales data
Analyst consensus
PharmaVitae explorer database
EXECUTIVE SUMMARY
Sandoz biosimilars overview
Sandoz biosimilars infrastructure
STRATEGIC INSIGHT
Sandoz biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Sandoz has focused on producing difficult-to-make biosimilars with the greatest sales potential
Aggressive M&A strategy has given Sandoz a strong market position
However, its biosimilar portfolio is difficult to value
KEY PRODUCTS
Overview
Sandoz biosimilar portfolio
Omnitrope
Overview
Somatropin market sizing
Key competitors
Sandoz biosimilar development
Clinical trials
Binocrit
Overview
Erythropoietin market sizing
Key competitors
Sandoz biosimilar development
Clinical trials

3. Zarzio
Overview
Filgrastim market sizing
Key competitors
Sandoz biosimilar development
Clinical trials
GP2013
Overview
Rituximab market sizing
Key competitors
Sandoz biosimilar development
Clinical trials
OPERATING PERFORMANCE
Operating costs and profit analysis
Operating costs and profit analysis, 2004–16
Operating cost ratio and profit margin analysis, 2004–16
CORPORATE STRUCTURE
Key findings
CORPORATE RELATIONSHIPS
Recent developments
APPENDIX
REFERENCES
EXCHANGE RATES
List Of Tables
Table: Sandoz – manufacturing and development metrics
Table: Sandoz – biosimilar portfolio
Table: Forecast somatropin sales ($m), 2011–16
Table: Biosimilar somatropin drugs, 2012
Table: Sandoz biosimilar Omnitrope clinical trials
Table: Forecast epoetin and darbepoetin sales ($m), 2011–16
Table: Biosimilar epoetin drugs, 2012
Table: Sandoz biosimilar erythropoietin clinical trials
Table: Forecast filgrastim and pegfilgrastim sales ($m), 2011–16
Table: Biosimilar filgrastim drugs, 2012
Table: Biosimilar pegfilgrastim drugs, 2012
Table: Sandoz biosimilar filgrastim clinical trials
Table: Forecast MabThera sales ($m), 2011–16

4. Table: Biosimilar rituximab drugs, 2012
Table: Sandoz biosimilar GP2013 clinical trials
Table: Sandoz operating revenues, costs, and profit ($m), 2004–10
Table: Sandoz operating revenues, costs, and profit ($m), 2010–16
Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2004–10
Table: Sandoz operating cost ratios and profit margin (as a percentage of total revenues), 2010–16
Table: Sandoz – deal activity and biosimilar deals
Table: Exchange rates, 2011
List Of Figures
Figure: The PharmaVitae Explorer
Figure: Sandoz biosimilars overview
Figure: Sandoz operating revenues, costs, and profit ($m), 2004–16
Figure: Sandoz – revenue by geographic region, 2011
Figure: Sandoz – revenue by segment, 2011
Browse more Research Reports @ http://www.reportsnreports.com/market-
research/company-profiles/
Contact Us:
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
+ 1 888 391 5441
Email: sales@reportsandreports.com
Connect With Us: